http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Number of Shares and Votes in Orexo
-
Orexo Discloses More Information About the Improved Market Access Position for Zubsolv® US in 2018
-
Orexo Publishes Prospectus and Applies for Listing of Bonds on Nasdaq Stockholm
-
Orexo Completes Early Redemption of Existing Bond Loan
-
Zubsolv® Receives Authorization for Treatment of Opioid Dependence in Europe
-
Orexo Issues Bonds of SEK 325 Million and Confirms Fulfilment of Condition Under Notice of Early Redemption
-
Orexo Announces Conditional Total Redemption of its Senior Unsecured Bonds
-
Orexo Appoints Nomination Committee and Publishes Financial Calendar 2017/2018
-
Orexo Signs Asset Purchase Agreement With Gesynta Pharma AB for OX-MPI
-
Orexo: Zubsolv® Gains Preferred Position on CVS Caremark 2018 Formulary
-
Number of Shares and Votes in Orexo
-
Issue and Repurchase of Class C Shares
-
Orexo Receives USD 2.5 Million Milestone Payment From AstraZeneca as OX-CLI Advances Into Clinical Trials
-
Report From Orexo AB´s Annual General Meeting, April 6 2017
-
Orexo Commences Patent Infringement Litigation Against Actavis for Their Generic Versions of Suboxone® and Subutex® Tablets in the US
-
Orexo Completes Bond Buyback Program
-
Number of Shares and Votes in Orexo
-
Orexo Completes Bond Buyback Program
-
Orexo Appeal Zubsolv® US District Court Decision
-
Orexo: Favorable outcome from Zubsolv® patent infringement litigation against Actavis
-
Number of shares and votes in Orexo
-
Orexo: FDA Approves Unique Low Dosage of Zubsolv®
-
Number of Shares and Votes in Orexo
-
Orexo Appoints Nomination Committee and Publishes Financial Calendar 2016/2017
-
Orexo: Issue and Repurchase of Class C Shares
-
Orexo Completes 1,080 Patient REZOLV Study and Reports on Improved Treatment of Opioid Dependent Patients
-
Brexit/EU Referendum Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

